Connect with us

Hi, what are you looking for?

Jewish Business News


Ackman supports Allergan’s $66 billion sale to Actavis

Bill Ackman facebook
Activist investor William “Bill” Ackman said on Tuesday he supports the $66 billion deal in which Actavis PLC will buy Allergan Inc and will withdraw his request for an Allergan special shareholder meeting.

Ackman, who had been fighting alongside Valeant Pharmaceuticals International Inc for control of Allergan, had called for the Allergan meeting to vote out board members and force the company to the table to consider their joint offer. The meeting is scheduled for Dec. 18.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

“We congratulate Actavis and Allergan on their announced transaction. As a result of the deal, we are withdrawing our special meeting request, ” Ackman said in an e-mailed statement.

Ackman’s comments come after Actavis said on Monday it would pay $219 per share for Allergan, billions more than Valeant was willing to pay. Ackman, who owns nearly 10 percent of Allergan, had paper gains of more than $2.3 billion based on that price.

CNBC reported earlier that Ackman will meet with executives from Actavis later this week.



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Copyright © 2021 Jewish Business News